Treatment-resistant depression in children and adolescents
Journal
Progress in Brain Research
Series/Report No.
0079-6123
Journal Volume
281
Start Page
1
End Page
24
ISSN
0079-6123
ISBN (of the container)
978-044322394-5
Date Issued
2023-01
Author(s)
Abstract
Major depressive disorder (MDD) in children and adolescents is a significant health problem, causing profound impairments in social, academic, and family functioning and substantial morbidity and mortality. Up to 15% of children and adolescents suffer from MDD, and a proportion, around 30 to 40% of them, failed to respond to initial selective serotonin reuptake inhibitor (SSRI) treatment. The only evidence-based recommendation is medication switching to another SSRI and augmentation with cognitive behavioral therapy. Newly developing treatment, including ketamine, transcranial magnetic stimulation, psychotherapy other than cognitive behavioral therapy, and combined pharmacotherapy with other interventions, requires further longitudinal controlled trials regarding efficacy and safety in this vulnerable population.
Subjects
Adolescents
Augmentation
Children
Cognitive behavioral therapy
Medication switching
Neuromodulation
Treatment-resistant depression
SDGs
Type
book part